$-0.10 EPS Expected for BioScrip Inc (BIOS)

October 14, 2017 - By Nellie Frank


Investors sentiment increased to 1.26 in Q2 2017. Its up 0.28, from 0.98 in 2017Q1. It is positive, as 13 investors sold BioScrip Inc shares while 26 reduced holdings. 17 funds opened positions while 32 raised stakes. 103.77 million shares or 6.20% more from 97.71 million shares in 2017Q1 were reported.
504,459 are held by Comml Bank Of New York Mellon. D E Shaw And Com Inc has 0.01% invested in BioScrip Inc (NASDAQ:BIOS). Jane Street Grp Incorporated Ltd Llc has 0% invested in BioScrip Inc (NASDAQ:BIOS). Benjamin F Edwards And stated it has 0% of its portfolio in BioScrip Inc (NASDAQ:BIOS). Manufacturers Life Ins The has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 99,569 shares. Geode Capital Management Ltd reported 0% stake. South State holds 12,700 shares or 0% of its portfolio. The New York-based Tiaa Cref Invest Mngmt Ltd Llc has invested 0% in BioScrip Inc (NASDAQ:BIOS). Goldman Sachs Group Incorporated Inc holds 32,137 shares. Ardsley Advisory Partners has invested 0.45% of its portfolio in BioScrip Inc (NASDAQ:BIOS). Royal Savings Bank Of Canada has invested 0% in BioScrip Inc (NASDAQ:BIOS). Northern Corp has 0% invested in BioScrip Inc (NASDAQ:BIOS). Sei Invests reported 0% in BioScrip Inc (NASDAQ:BIOS). Rhumbline Advisers reported 130,122 shares. 57,984 were accumulated by Citadel Advsrs Ltd Liability Co.

Analysts expect BioScrip Inc (NASDAQ:BIOS) to report $-0.10 EPS on November, 6.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.1 EPS. After having $-0.11 EPS previously, BioScrip Inc’s analysts see -9.09 % EPS growth. It closed at $2.61 lastly. It is down 29.17% since October 15, 2016 and is downtrending. It has underperformed by 45.87% the S&P500.

BioScrip Inc (NASDAQ:BIOS) Ratings Coverage

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip had 10 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained BioScrip Inc (NASDAQ:BIOS) rating on Thursday, June 8. Jefferies has “Buy” rating and $300 target. Dougherty & Company maintained the shares of BIOS in report on Wednesday, August 12 with “Buy” rating. On Tuesday, August 11 the stock rating was downgraded by SunTrust to “Buy”. The company was initiated on Tuesday, January 3 by Lake Street. The stock of BioScrip Inc (NASDAQ:BIOS) earned “Buy” rating by SunTrust on Thursday, August 10. The firm has “Buy” rating by Jefferies given on Tuesday, July 25. The company was maintained on Wednesday, August 9 by Jefferies.

BioScrip, Inc. is engaged in providing infusion solutions. The company has market cap of $332.71 million. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. It currently has negative earnings. The Firm operates through Infusion Services segment.

Another recent and important BioScrip Inc (NASDAQ:BIOS) news was published by Globenewswire.com which published an article titled: “BioScrip Announces Availability of ALS Home Infusion Therapy” on October 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com